| Ident. | Authors (with country if any) | Title |
|---|
| 000348 (2011) |
Nicola Z. Hobbs [Royaume-Uni] ; Amy V. Pedrick [Royaume-Uni] ; Miranda J. Say [Royaume-Uni] ; Chris Frost [Royaume-Uni] ; Rachelle Dar Santos [Canada] ; Allison Coleman [Canada] ; Aaron Sturrock [Canada] ; David Craufurd [Royaume-Uni] ; Julie C. Stout [Australie] ; Blair R. Leavitt [Canada] ; Josephine Barnes [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni] ; Rachael I. Scahill [Royaume-Uni] | The Structural Involvement of the Cingulate Cortex in Premanifest and Early Huntington's Disease |
| 000383 (2011) |
Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Synergistic Antidyskinetic Effects of Topiramate and Amantadine in Animal Models of Parkinson's Disease |
| 000964 (2010) |
Richard Dodel [Allemagne] ; Annika Spottke [Allemagne] ; Alexander Gerhard [Royaume-Uni] ; Alexander Reuss [Allemagne] ; Sylvia Reinecker [Allemagne] ; Nicole Schimke [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Friederike Sixel-Döring [Allemagne] ; Birgit Herting [Allemagne] ; Christoph Kamm [Allemagne] ; Thomas Gasser [Allemagne] ; Martin Sawires [Autriche] ; Felix Geser [Autriche] ; Martin Köllensperger [Autriche] ; Klaus Seppi [Autriche] ; Manja Kloss [Allemagne] ; Martin Krause [Allemagne] ; Christine Daniels [Allemagne] ; Günther Deuschl [Allemagne] ; Silke Böttger [Allemagne] ; Markus Naumann [Allemagne] ; Axel Lipp [Royaume-Uni] ; Doreen Gruber [Allemagne] ; Andreas Kupsch [Allemagne] ; YANSHENG DU [États-Unis] ; Federico Turkheimer [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Thomas Klockgether [Allemagne] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Carmen Schade-Brittinger [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Karla Eggert [Allemagne] | Minocycline 1-Year Therapy in Multiple-System-Atrophy: Effect on Clinical Symptoms and [11C] (R)-PK11195 PET (MEMSA-Trial) |
| 000A03 (2010) |
Annu Aggarwal [Inde] ; Susanne A. Schneider [Allemagne, Royaume-Uni] ; Henry Houlden [Royaume-Uni] ; Monty Silverdale [Royaume-Uni] ; Reema Paudel [Royaume-Uni] ; Coro Paisan-Ruiz [Royaume-Uni] ; Shrinivas Desai [Inde] ; Mihir Munshi [Inde] ; Darshana Sanghvi [Inde] ; John Hardy [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Mohit Bhatt [Inde] | Indian-Subcontinent NBIA: Unusual Phenotypes, Novel PANK2 Mutations, and Undetermined Genetic Forms |
| 000B34 (2010) |
Pablo Arias [Espagne] ; Jamile Vivas [Espagne] ; Kenneth L. Grieve [Espagne, Royaume-Uni] ; Javier Cudeiro [Espagne] | Controlled Trial on the Effect of 10 Days Low-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) on Motor Signs in Parkinson's Disease |
| 000D01 (2009) |
Annie W. Hsu [États-Unis] ; Panida A. Piboolnurak [États-Unis] ; Alicia G. Floyd [États-Unis] ; Qiping P. Yu [États-Unis] ; James E. Wraith [Royaume-Uni] ; Marc C. Patterson [États-Unis] ; Seth L. Pullman [États-Unis] | Spiral Analysis in Niemann-Pick Disease Type C |
| 000D31 (2009) |
Iracema Leroi [Royaume-Uni] ; Ross Overshott [Royaume-Uni] ; E. Jane Byrne [Royaume-Uni] ; Emily Daniel [Royaume-Uni] ; Alistair Burns [Royaume-Uni] | Randomized Controlled Trial of Memantine in Dementia Associated with Parkinson's Disease |
| 001045 (2008) |
Monty A. Silverdale [Canada, Royaume-Uni] ; Susanne A. Schneider [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Anthony E. Lang [Canada] | The Spectrum of Orolingual Tremor : A Proposed Classification System |
| 001C35 (2006) |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets : Mediation by D2, not D3, dopamine receptors |
| 001C87 (2005) |
Monty A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Canada] | Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease |
| 002078 (2004) |
Susan Fox [Royaume-Uni] ; Montague Silverdale ; Mark Kellett ; Rhys Davies ; Malcolm Steiger [Royaume-Uni] ; Nicholas Fletcher [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie | Non-subtype-selective Opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease |
| 002391 (2003) |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 002440 (2003) |
Peter Hagell [Suède] ; Diane Whalley [Royaume-Uni] ; Stephen P. Mckenna [Royaume-Uni] ; Olle Lindvall [Suède] | Health status measurement in Parkinson's disease: Validity of the PDQ-39 and Nottingham Health profile |
| 002450 (2003) |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease |
| 002471 (2003) |
Gregorio Segovia [Royaume-Uni, Espagne] ; Francisco Mora [Espagne] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease |
| 002517 (2003) |
David Mckee [Royaume-Uni] ; Paul Talbot [Royaume-Uni] | Chorea as a presenting feature of variant Creutzfeldt-Jakob disease |
| 002601 (2002) |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 002630 (2002) |
Susan H. Fox [Royaume-Uni] ; Mark Kellett [Royaume-Uni] ; A. Peter Moore [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia |
| 002834 (2002) |
Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Characterisation of striatal NMDA receptors involved in the generation of Parkinsonian symptoms: Intrastriatal microinjection studies in the 6-OHDA-lesioned rat |
| 002952 (2001) |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
| 002C80 (2000) |
Susan H. Fox [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease |
